Diffuse mesothelioma
A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma
Annals of Oncology.. 2006 Nov 27; [Epub ahead of print] [Link] T. D. Yan 1, L. Welch 2, D. Black 3, and P. H. Sugarbaker 1 * 1 Program in Peritoneal Surface Oncology, Washington Cancer Institute, Washington Hospital Center, Washington, DC 2 Center to Protect Worker’s Rights, Silver Spring, MD, USA 3 School of Public…
Read MorePrognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma
Archives of Pathology and Laboratory Medicine. Vol. 130, No. 11, pp. 1654–1661. [Link] Carlos A. Cerruto, MD; Erwin A. Brun, MD; David Chang, MD; Paul H. Sugarbaker, MD From the Department of Pathology, Washington Hospital Center, Washington, DC (Drs Cerruto and Brun); Westat, Rockville, Md (Dr Chang); and the Washington Cancer Institute, Washington, DC (Dr…
Read MoreSex difference in diffuse malignant peritoneal mesothelioma
British Journal of Surgery. 2006 Oct 18; [Epub ahead of print] [Link] Yan TD, Popa E, Brun EA, Cerruto CA, Sugarbaker PH. Washington Cancer Institute, Washington, DC, USA. Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is rare and in the past has proved an invariably fatal disease. Female patients have been reported to have an…
Read MorePathological recognition of diffuse malignant mesothelioma of the pleura: the significance of the historical perspective as regards this signal tumor
Seminars in Diagnostic Pathology. 2006 Feb;23(1):25-34. [Link] Mark EJ, Kradin RL. Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA. Mark@helix.mgh.harvard.edu Abstract Diffuse malignant mesothelioma (DMM) is a distinctive tumor which provides an uncommon opportunity to observe the gradual appreciation and increasing incidence of a new disease. DMM is a new…
Read MoreThe biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma
Seminars in Diagnostic Pathology. 2006 Feb;23(1):35-43. [Link] Davidson B, Risberg B, Berner A, Bedrossian CW, Reich R. Department of Pathology, Norwegian Radium Hospital-National Hospital, University of Oslo, Oslo, Norway. ben.davidson@radiumhospitalet.no Abstract Recent improvements in immunohistochemistry panels used for differentiating ovarian serous carcinoma/primary peritoneal carcinoma (OC/PPC) from diffuse malignant peritoneal mesothelioma (DMPM) have resulted in improved…
Read MoreMorbidity and Mortality Assessment of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma—A Prospective Study of 70 Consecutive Cases
Annals of Surgical Oncology. 2006 Oct 10; [Epub ahead of print] [Link] Yan TD, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH. Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington Hospital Center, 106 Irving Street, NW, Suite 3900N, Washington, DC, 20010, USA, Paul.Sugarbaker@medstar.net. Abstract Background: Although many reports regarding morbidity and mortality of cytoreductive surgery…
Read More
Skip to content